RESEARCH DOSSIER
Term Life Insurance Renewal and Conversion Design
Abstract. Term life insurance protects an identifiable death-contingent financial interest for a defined period while allocating uncertainty about subsequent health, protection needs, and future insurability between policyholder and insurer. Guaranteed renewal and contractual conversion rights change that allocation. Renewal permits continuation of death protection under the applicable policy rules, commonly without new evidence of insurability but often at a substantially higher premium after an initial level-premium period. Conversion permits qualifying term coverage to be replaced with an eligible permanent life contract without new medical underwriting, subject to deadlines, amount limits, product availability, risk-class provisions, and other terms. These options have economic value because health and insurance eligibility evolve after issue. Their value and cost are endogenous to the same decisions that alter the composition of the surviving insured pool. This monograph reconstructs renewal and conversion from actual consumer disclosures, specimen policy provisions, insurance regulation, actuarial guidance, peer-reviewed contract theory, and insured-life experience studies. It distinguishes a renewal guarantee from guaranteed premiums, a conversion privilege from an unrestricted right to a particular permanent product, contractual conversion from replacement and term-to-term exchange, and pricing assumptions from evidence about realized behavior. The 2009–2023 Society of Actuaries Research Institute and LIMRA conversion study covers more than 600,000 conversions among participating U.S. insurers; those observations are combined with earlier conversion research and post-level term studies without treating them as representative of all jurisdictions or every policy form. Transparent scenario mathematics illustrates premium shock, conditional selection, option cost, and the limits of simple valuation. Comparative sections consider U.S. contract law and supervisory materials, Canadian specimen terms, European insurance distribution and product-governance rules, and IFRS 17 accounting boundaries. The analytical conclusion is that renewal and conversion design is a dynamic allocation of future classification risk, protection continuity, and exercise flexibility. It must be evaluated jointly through premium paths, exercise eligibility, insured-state transitions, lapse and conversion behavior, mortality after exercise, permanent-product guarantees, and intelligible disclosure. Better exercise access can protect persons who have become difficult to insure while materially changing expected insurer cash flows. More restrictive options can reduce option cost while diminishing the policyholder's expected continuity value. The dossier provides auditable decision criteria and research implications without proposing a new named theory or claiming original population estimates.
Keywords: Term life insurance; guaranteed renewability; renewable term; level-premium term; annually renewable term; conversion privilege; guaranteed insurability; permanent insurance; attained-age premiums; term-to-term exchange; shock lapse; adverse selection; classification risk; mortality; contingent claims; dynamic contracts; policyholder behavior; policy wording; life-insurance product governance; IFRS 17.
Introduction
A life insurer can underwrite a person today but cannot know the person's health in fifteen years. A term policy addresses an immediate risk of death during a stated coverage period. A renewal or conversion clause addresses a second risk: that the same person may still need protection after the original pricing period yet face materially different insurability, available products, and insurance costs. The coverage contract thereby determines who holds the right to decide later and what the other party must do when that right is exercised.
The distinction is visible in the NAIC description of renewable and convertible term (National Association of Insurance Commissioners, n.d.). Renewable term allows continuation without proof of insurability under specified conditions; convertible term provides an option to obtain eligible permanent insurance. New York's Department of Financial Services describes how renewal avoids renewed health qualification and how the conversion exercise period and attained-age premium basis must be understood separately (New York State Department of Financial Services, n.d.). The general consumer descriptions are starting points. The operative rights exist in policy wording, relevant law, and the procedures for exercising an option.
The dossier asks three connected questions. How should renewal and conversion be defined and distinguished in a contract whose premium, risk class, insurer obligations, and eligibility change with time? How do those options affect prospective claims, policyholder welfare, financial reporting, and the distribution of insured risks? Which observed empirical patterns can support design and valuation decisions, and where do available data leave critical quantities unidentified?
The analysis uses documentary comparison and elementary prospective actuarial valuation, then reconciles those constructions with published empirical research. An insurer's illustrated premium schedule is evidence about one contract form, not the prevalence of such terms across the industry. A published experience study is evidence about its study population and exposure definitions, not a universal transition matrix. A regulatory model is distinguished from enacted law; a supervisory principle is distinguished from a policy benefit; and an accounting measurement boundary is distinguished from an underwriting guarantee. All hypothetical calculations are labeled and intentionally reproducible.
Several neighboring subjects have their own scientific homes within Insurance by Bogdanova. Mortality table construction, full reserve mathematics, replacement regulation, insurance distribution, disability riders, and permanent-account crediting are treated here only where they change the renewal or conversion decision. The principal scientific connection is Life Insurance, with additional relationships to Insurance Contract Law, Insurance Consumer Protection, and Insurance Governance and Market Conduct. The single dossier retains its own canonical identity.
Definitions, Historical and Documentary Foundation
The contract, its duration, and the option holder
A term life contract promises a specified death benefit if an insured person dies while coverage is in force and the contract's conditions are satisfied. Its economic object is the transfer of a mortality-contingent payment obligation over a bounded horizon. Policies commonly have a level face amount, although decreasing-face and other structures exist. The premium may be level for part of the term, change according to a schedule, or renew annually at attained-age rates. A description of “ten-year term” can mean a ten-year level-premium period, a ten-year contractual coverage period, or a renewal cycle; the precise contract determines which meaning applies.
Renewability is a contractual continuation right. If guaranteed renewable without new evidence of insurability, the policyholder who satisfies the policy's rules can extend or continue eligible coverage despite later deteriorating health. A guaranteed right to continue is economically distinct from a guaranteed unchanged price. The New York life-insurance consumer guide explicitly describes rising premiums in renewable-term coverage (New York State Department of Financial Services, n.d.). An annually renewable term contract may have an annually increasing guaranteed premium schedule; a ten- or twenty-year level-premium contract may have a step change after the initial period while its underlying death protection remains renewable.
Conversion is a contractually specified option to exchange eligible term protection for specified forms of permanent coverage, usually without a fresh health assessment. The option can preserve original underwriting classification or apply a contractual class mapping, but the replacement permanent policy normally has new premiums corresponding to attained age and eligible products at conversion. The SOA 2016 conversion experience project defines the studied exercise as a term policyholder moving to permanent coverage without underwriting (Society of Actuaries, 2016). Conversion is consequently a form of deferred access to underwriting classification, rather than a promise that the original term premium will finance permanent coverage indefinitely.
Conversion is not synonymous with policy replacement in the regulatory sense. Replacement may involve terminating one contract and purchasing another, sometimes with different insurers, and triggers jurisdiction-specific disclosure duties. Nor is it the same as a term-to-term exchange privilege, under which an insurer may offer a new term plan without new evidence within narrower constraints. A contractual conversion can be partial, subject to minimum benefit, age ceilings, specified elected benefits, and application timing. Each element changes the option payoff and operational outcome.
Contract documents as primary evidence
Actual policy language demonstrates why the descriptive category “convertible term” has limited precision. A Canadian RBC Simplified Term disclosure describes guaranteed annual renewal after the initial term, rising renewal premiums, and conversion before the policy anniversary nearest age 71 to the permanent products offered for conversion at the exercise date (RBC Insurance, n.d.). The clause is specific to the disclosed product and applicable contract. It shows that a renewal premium schedule, conversion deadline, in-force condition, and contemporaneous permanent-product menu can coexist.
The Equitable Term specimen policy provides a distinct design: for listed renewable-and-convertible term coverages, a conversion window tied to the anniversary nearest the oldest insured person's 71st birthday, requirements concerning amount and permanent-plan minimums, and an express risk-class mapping that can depend on the conversion anniversary (Equitable Life of Canada, specimen policy). In a joint-life specimen, these details cannot simply be transposed to a single-life U.S. contract. The comparison demonstrates that even when medical evidence is waived, contract mapping between old and new rating classes is a decisive underwriting rule.
The Equitable specimen also constrains eligible amounts and the minimum and maximum values permitted for the replacement permanent policy. These operational requirements matter as much as the general promise of guaranteed insurability. A requested conversion can therefore be impossible for a particular face amount or selected permanent product even when the insured remains within the main age window. The contract conditions govern that assessment.
A policy-design research record should capture the actual policy schedule, issue edition, endorsements, relevant state or country approval, age basis, premium table, right-holder identity, eligible permanent plans, conversion exercise notice, minimum and maximum amounts, split-conversion rules, existing riders, and effective dates. A marketing statement is insufficient to determine a legal right when those instruments differ. A prospectus, specimen form, and personal policy schedule may define different product families or contract versions.
Why long-term commitments enter the analysis
The economic problem has a long-term contracting structure. A policyholder can usually stop paying at future dates. An insurer may be obliged to continue or convert eligible coverage on a predetermined underwriting basis. As the holder acquires private information about health or changing need, the probability of exercising the option can diverge across risk classes. Hendel and Lizzeri's study of commitment in life insurance (2003) found evidence consistent with front-loaded premiums and partial consumer commitment in a market where long-term classification risk matters. This result supplies an economic explanation for why a level-premium policy may charge more in early years than contemporaneous expected mortality alone would require. It does not prove that every front-loaded policy is efficient or quantify the value of a particular conversion rider.
A long-term guaranteed right can be valuable even when never exercised. At issue the purchaser pays for a contingent ability to act if later health or financial conditions change. The insurer prices a probability distribution over future health states, continuation decisions, available permanent products, and death claims. The research focus therefore includes unused options and the people who terminate before exercise, not only recorded conversions.
Terms and distinctions used in this monograph
| Term | Operational meaning | Critical distinction |
|---|---|---|
| Initial level-premium period | Stated years with scheduled unchanged premium | Its end need not terminate renewable coverage |
| Guaranteed renewal | Continued eligible coverage without fresh evidence of insurability | Premium may increase under a stated renewal schedule |
| Annually renewable term | One-year pricing/coverage cycles with defined continuation rules | Different risk exposure from a new fully underwritten issue |
| Conversion option | Eligible movement from term to permanent protection | New permanent premium and eligible product may vary |
| Exchange privilege | Contractual move between eligible term products | A distinct option, not automatically permanent conversion |
| Attained-age rate | Premium determined partly by age on conversion or renewal | Health class mapping remains separately contractual |
| Shock lapse | Concentrated terminations around a substantial premium change | Conditional surviving mortality can change materially |
| Post-conversion mortality | Claims experience after movement to permanent coverage | Requires conversion-specific exposure, timing and selection adjustment |
| Classification risk | Future re-underwriting class or eligibility uncertainty | Option value depends on future health information and exercise |
Renewal Price Paths
Premium guarantees and the shape of a renewal curve
A renewal premium path is a function of attained age, policy duration, guaranteed rates, face amount, any permitted rate adjustments, taxes, and the contract's schedule. A level-premium term product may deliberately hold the price fixed while insured mortality rates rise with age. The transition from the level period to a subsequent annually renewable segment can then produce a large price change. This premium jump is not necessarily evidence that the insurer has re-underwritten the particular insured person; it may be the scheduled contract price for a renewal cohort with an older attained age.
One useful representation defines the premium due at duration t as P(t, a, c, F, z), where a is attained age, c is the conversion or renewal risk class as contractually applicable, F is the face amount, and z represents the relevant plan and contractual conditions. A guaranteed schedule fixes or bounds parts of that function at inception. Where the contract allows non-guaranteed changes, the pricing assumption and legally guaranteed maximum need separate disclosure. The U.S. Actuarial Standard of Practice No. 54 (Actuarial Standards Board, 2018) addresses the professional analysis of life-product pricing, assumptions, risk, and communication within its applicable scope; it is a professional standard for covered U.S. actuarial work, not a universal statutory pricing formula.
The insurer's economic premium adequacy depends on the composition of the individuals who keep the contract at each renewed price. A renewal right that forbids new health underwriting has a different conditional risk pool from a freshly underwritten contract. When a premium rises sharply, relatively healthy persons may seek competitively priced new insurance while people who have become harder to insure value the existing guarantee more. Price and lapse behavior can therefore jointly increase the death-claim rate per continuing policy even as the number of continuing policies falls. The important state variable is the health composition among those actually remaining insured.
A reproducible premium illustration
Consider a hypothetical $500,000 face-amount policy issued at age 40 with a $420 annual premium during ten level-premium years. Assume that a five-year post-level renewable schedule, quoted solely for illustration, is $3,500, $4,200, $5,040, $6,048, and $7,257.60 for years 11–15. The first renewal premium equals 8.33 times the initial premium. This is a constructed schedule, not a rate quotation or an assertion about a particular insurer. The undiscounted total of those five post-level premiums is $26,045.60 conditional on continuous payment. At a 4% effective annual discount rate, their present value at the start of year 11 is the sum of each scheduled premium discounted by its timing; discount timing must be specified consistently with whether premiums are paid in advance or arrears.
An unqualified comparison of the $420 and $3,500 figures is incomplete. The level-premium years combined mortality protection with intertemporal premium smoothing, while the post-level years may involve an older, increasingly selected portfolio. To assess the policyholder's actual opportunity set, compare the guaranteed renewal schedule, any valid conversion alternative, and realistically available re-underwritten new cover, including potential refusal or exclusions. Re-underwritten replacement rates for a deteriorated health state may be unavailable. An illustrative price advantage for a healthy buyer cannot be assumed for every insured person.
Lapse and survival conditionality
Let q_x^H and q_x^I be one-year mortality probabilities for a hypothetical healthier group and impaired-health group at a renewal point. Suppose 80% of an initially exposed cohort is in the healthier group with mortality 0.003, while 20% is in the impaired group with mortality 0.012. Its pre-decision weighted mortality probability is 0.8×0.003 + 0.2×0.012 = 0.0048. If 10% of healthier and 65% of impaired individuals retain the renewal option, the renewal retention rate becomes 0.8×0.10 + 0.2×0.65 = 0.21. Among those who retain, the weighted one-year mortality becomes (0.8×0.10×0.003 + 0.2×0.65×0.012)/0.21 = 0.008571. Mortality conditional on renewal is approximately 1.79 times the original cohort average.
Every figure in this example is assumed and explicitly hypothetical. It demonstrates a mathematical selection mechanism; it is not an estimate from the SOA data or an insurer's experience. It also assumes mutually exclusive health groups and consistent risk exposure. If mortality rates are conditional on survival to the decision date, the group proportions must be estimated for that same survivor population. Mixing issue-date proportions with later conditional mortality introduces an error that can overwhelm the intended comparison.
Historical experience supports the need to model this mechanism. The SOA post-level term project (Rozar, Rushing, and Willeat, 2010) examined lapse and mortality where policies pass out of a level-premium period. The subsequent U.S. post-level term experience update (Bradfield et al., 2021) studies that same critical transition with updated observations. These research programs reinforce that post-level lapse and mortality deserve a joint evaluation; they do not provide a single permanent mortality multiplier to be imposed on all renewal products.
Cash-flow timing and stress paths
A conventional expected-value calculation can be built from an at-risk population N(t), a conditional retention rate r(t), a mortality rate among retained exposures q(t | retained), and a benefit F(t). A simplified one-year expected death benefit is N(t) r(t) q(t | retained) F(t), subject to exact exposure and claim-timing conventions. Expected renewal premium receipts are N(t) r(t) P(t) when the annual premium is paid at the beginning of the year. Administrative expenses, claims expenses, taxes, reinsurance, discounting, deaths, and timing adjustments are then added in an explicit valuation model. The retained-risk mortality must not be estimated independently of the retained population if the same policyholder factors drive both.
Stress testing should include at least a moderate and a severe post-level price jump, healthier-than-expected lapse, higher-than-expected retention among impaired lives, varying conversion exercise before the jump, and delayed versus accelerated notification of upcoming changes. Each stress changes future insurer claims and collected premiums, as well as customer protection continuity. A premium shock that induces many healthy exits may raise average mortality per continuing policy yet still reduce aggregate claims because the portfolio shrinks. Aggregate and conditional measures answer different questions.
Discounting and renewal as a contingent value
The expected present cost of a renewal guarantee is an incremental comparison between the contractual guaranteed-renewal world and a specified alternative world in which future coverage could be risk-priced or denied after re-underwriting. Without a defined counterfactual, “the value of renewability” has no unique monetary amount. A valid appraisal requires the distribution of future health states, future premium rules, exercise behavior and lapse, future face amounts, the selected basis for discounting, and the extent to which guarantee cost has already been collected during early policy years. Insurer economic cost, statutory reserve, IFRS 17 fulfilment measurement, and customer willingness to pay are different measures of the same contractual rights.
Conversion Option Valuation
The conversion right as an embedded contingency
A conversion privilege permits an eligible term policyholder to replace specified term coverage with an eligible permanent-life contract according to the governing policy terms. The economically important guarantee is the ability, subject to those terms, to obtain the replacement without supplying new evidence of insurability. Some contracts permit conversion of all or part of the term face amount; some constrain the eligible permanent products, maximum conversion age, time since issue, or final date before term expiry. The contract may preserve the original underwriting classification, apply a conversion-specific classification schedule, or contain a carefully described mechanism for class mapping. A converted policy typically charges the permanent product's applicable rate at the new policy's attained age or other contractual age basis. None of these provisions should be presumed from the marketing word “convertible” alone.
The distinction between conversion and ordinary renewal begins with the protected option. Renewal generally preserves term protection for an additional policy period, often at an older attained-age premium. Conversion replaces the contract or its designated portion with a new policy structure and a longer coverage horizon. The policyholder can exercise one right without possessing the other. A converted contract may then create its own surrender values, premium obligations, participation rights, investment-linked provisions, or guarantees. These attributes belong to the eligible permanent product, not automatically to the pre-conversion term contract. The Equitable sample term policy (Equitable, 2025) provides one Canadian product illustration of documented eligibility, risk-class mapping, and conversion conditions. The particular policy wording controls that example.
A RBC Insurance conversion disclosure illustrates another product-specific design, with renewal and conversion eligibility and age limits particular to that insurer's coverage. The comparison demonstrates variation in contract architecture within one national market, rather than a universal Canadian conversion rule. Contract reviewers should always distinguish an insurer website's contemporaneous marketing description, a specimen policy, a personalized schedule, and the issued contract plus endorsements. Their evidentiary authority differs.
Contingent-state representation
Let the term policyholder's health and underwriting information at a future exercise date t be represented by state h, and let E(t,h) indicate contractual eligibility. If the policyholder exercises, an eligible permanent policy produces a stream of future premiums and contingent death benefits; if the policyholder does not exercise, the alternatives may include term renewal, replacement by new underwriting, partial coverage, or no insurance. The policyholder's conversion value is the incremental welfare or financial value of the best feasible eligible conversion outcome relative to the best feasible alternative, conditional on health and available information. The insurer's economic value of the conversion guarantee is correspondingly assessed using the incremental risk and expense cash flows of actual and projected exercisers, allowing for premiums already paid for the privilege.
A schematic prospective insurer cash-flow term for exercised conversion may be written:
PV_conversion = E[1{eligible and exercises} × (PV(permanent death claims + expenses) − PV(permanent premiums))].
This expression is deliberately incomplete as a product reserve formula: it omits tax, risk margins, capital, reinsurance, acquisition expenses, discount rate uncertainty, and the interaction with lapse or renewal of the original term contract. It identifies the contingent logic, not an accounting measurement. The correct object for the incremental option cost is the difference between contract designs with and without the conversion entitlement on a consistent valuation basis. Treating the full present value of permanent insurance claims as the conversion option cost double-counts premiums and confuses an insurance liability with the value of the special contractual right.
This distinction parallels the general actuarial treatment of options and guarantees. For a standard governing U.S. life-product pricing work, the ASOP No. 54 pricing standard (Actuarial Standards Board, 2018) provides the professional framework for pertinent assumptions and risk evaluation. For financial reporting under IFRS 17, option-related future cash flows are assessed within the applicable insurance contract boundary rather than equated with a proprietary renewal-option price. The IASB's contract-boundary discussion paper (IFRS 17 Transition Resource Group, 2018) is a focused interpretive source about boundaries and policyholder options, read together with the operative IFRS 17 standard (IASB, 2017, effective 2023). A technical accounting memo, a pricing projection, and a regulatory-reserve calculation are separate deliverables.
Exercise behavior and selection
The owner of a conversion right receives particularly valuable protection when a worsening health state makes new fully underwritten permanent insurance more expensive or inaccessible. The insurer's pool of converted policies can therefore have a different mortality distribution from the entire in-force term portfolio. It may also differ from the pool that renews term coverage after a level-premium period, because conversion prices, age eligibility, premium affordability, consumer advice, and the permanence of the new benefit shape selection. Neither all conversion exercisers nor all term renewers are necessarily impaired; the direction of selection requires observed exposures and appropriate controls.
The SOA 2000–2014 conversion study (Meisinger et al., 2016) establishes a historical U.S. insured-life experience base focused on term conversions. The later SOA predictive conversion research (Xu et al., 2017) investigated methods for predicting conversion behavior and post-conversion mortality, reinforcing that exercise probabilities and mortality cannot simply be inferred from all original term issuances. In a suitable multistate model, policyholders transition among in-force term, renewed term, converted permanent, lapsed, expired, and deceased states according to distinct transition intensities. Some transitions compete: death before an intended exercise date eliminates an available future conversion, and an expiry date may eliminate an unexercised right.
The state structure helps identify practical errors. Counting a conversion as a lapse without recognizing the newly issued permanent contract exaggerates term discontinuance and omits retained insurer exposure. Counting a conversion as identical to an ordinary renewal overstates continuity of product form. Using the insurer's whole-life mortality table for converted lives assumes away the very health selection the guarantee creates. A policy-administration system needs transaction codes, linked policy identifiers, dates, face amounts before and after exercise, underwriting classes, and death claims to identify these pathways.
Conversion pricing and the exercise frontier
The policyholder has an incentive to exercise when the perceived value of permanent coverage, including the avoided health requalification requirement, exceeds the incremental present burden of permanent premiums and other changes. Health deterioration can shift this frontier toward exercise; falling coverage needs, high permanent premiums, liquidity constraints, and the availability of affordable alternative insurance can shift it away. Selection therefore interacts with affordability. A seriously impaired insured may value guaranteed conversion highly but be unable to afford the permanent premium. An actuarial model that equates medical impairment with certain exercise will overstate conversion take-up and may misrepresent which health states ultimately appear in the permanent portfolio.
A numerical illustration clarifies a one-period component of the guarantee. Suppose two otherwise comparable future contracts have annual permanent premiums of $2,000 and $3,360 because the second is newly underwritten for an impaired health state. If the original term contract allows conversion at the first rate under its actual risk-class rules, the immediate annual price difference is $1,360. This is not the complete value of the guarantee: a complete valuation discounts all future differences, includes mortality-dependent benefit payments, policy survival and lapses, and recognizes the amount of coverage actually desired. For illustration only, if that $1,360 annual difference persisted for ten end-of-year payments, with 95% deterministic exercise assumed at the outset and 4% annual discounting, the present value of the difference at the exercise date would equal 0.95 × 1,360 × (1 − 1.04^−10)/0.04 ≈ \$10,479.28. This is a simplified annuity calculation for a price difference, not an insurer's incremental cost, market premium, or empirically estimated value of guaranteed insurability. Mortality, contract lapse, and availability of replacement could materially change it.
Reserving and contract boundary
A conversion provision raises two separate timing questions: when the insurer becomes bound to provide later coverage and which cash flows are assigned to the existing accounting contract. The IFRS 17 contract requirements establish a reporting framework for insured obligations within the contract boundary. The New Zealand IFRS 17 standard text reproduces detailed guidance that includes consideration of renewing or converting contracts in measuring insurance risks and cash flows within the proper boundary. Applicability depends on substantive rights and obligations, including the insurer's practical ability to reassess and fully price risk. Product labels do not by themselves determine the boundary.
The insurer should reconcile conversion assumptions across profitability projections, statutory or solvency reserves, financial-statement measurement, reinsurance treaties, and risk management. A reinsurance treaty that excludes converted business, prices it differently, or imposes capacity and notification requirements changes net exposure even though the underlying policyholder right remains. An embedded option can create tail risk through the concentration of exercise by higher-risk insureds and through unexpected future product availability. Actuarial governance should document how prospective permanent premiums, future product sets, and guaranteed underwriting class mapping are represented rather than silently substituting a current sales illustration for a binding entitlement.
Contractual Eligibility and Disclosure
The operational definition of eligibility
Eligibility can be expressed as a conjunction of contractual conditions. The policy must remain in force under the appropriate grace and payment rules; conversion must occur during an authorized time window; the insured's age and the requested conversion amount must satisfy applicable limits; the selected permanent product must be within the permitted choices; and any prerequisites concerning documentation, notification, riders, ownership, and administrative receipt must be fulfilled. The exact conditions vary by insurer and jurisdiction. A life insurance company may have discretion to select a set of permanent policies for conversion, but the terms governing that discretion must be read from the actual contract and applicable local law.
The Equitable term specimen policy (Equitable, 2025) permits a document-level examination of conditions such as eligibility and risk classification; the RBC simplified-term policy specimen provides a second document with distinct product wording. Their differences supply a useful empirical research design: compare contract text on maximum age, application timing, face amount, partial conversion, premium basis, rider treatment, underwriting evidence, and the insurer's product list. A public brochure can explain a product to buyers but is insufficient to prove the wording of every previously issued contract generation.
Guaranteed renewable, guaranteed convertible, and guaranteed insurability
Three expressions often appear together in retail explanations. Guaranteed renewable term means continued term protection in the defined future periods without new evidence of insurability, conditioned on contractual requirements. Guaranteed convertible term identifies the privilege to change specified term coverage into another eligible insurance form without new evidence of insurability. A guaranteed-insurability option in a broader life-insurance context can permit increases or additions to coverage on qualifying dates or events, with its own amount limits and premiums. The rights may overlap but are not interchangeable. An option that merely preserves the original face amount cannot be described as a right to increase the amount, and a permanent-policy conversion is not equivalent to perpetual term renewal at the original level premium.
The NAIC life insurance consumer resource (NAIC, accessed 2026) explains the major term and permanent forms, including common renewal and conversion concepts for U.S. consumers. The New York life insurance guide (New York Department of Financial Services, accessed 2026) similarly provides jurisdiction-specific consumer education. Neither general explanation substitutes for a policy's dated provisions. An insurer promising conversion until a stated age may calculate that age on an insurance-age basis that differs from calendar birthdays; the actual contract's definition decides the deadline. The conversion deadline may also precede the term policy's final expiry. An age-eligible insured can therefore lose conversion rights by missing a separate earlier contractual date.
Contract disclosure and communication timing
Effective disclosure should allow policyholders to understand at least five operational facts: the renewal dates and the size of future scheduled premiums; whether those future premiums are guaranteed and for how long; the earliest and latest conversion exercise dates; the permanent products and underwriting classifications actually available under the contract; and whether a conversion changes riders, beneficiary designations, cash value, contestability or suicide provisions under applicable law and form language. These items have financial and legal consequences. A disclosure containing the phrase “convertible without a medical exam” may be materially incomplete if it omits the relevant age restriction, eligible products, premium basis, or limits on converting part of the face amount.
Communication design should separate hard contractual deadlines from advisory reminders. An insurer can send reminders well before the last conversion date, but a reminder is not itself the legal source of the deadline. For compliance, the firm needs a reliable linkage among the original issued form, endorsements, the current policy administration record, and the applicable law at issue. A notification system that uses only today's marketing brochure risks assigning new-product provisions to historical contracts. Similarly, a marketing description of a renewal premium increase cannot replace the guaranteed rate table in the issued schedule when the two are different.
The EU Insurance Distribution Directive (European Parliament and Council, 2016) establishes distribution and conduct requirements for insurance products within the European framework, including duties concerning customers' demands and needs. The EU product oversight regulation (European Commission, 2017) details product approval, target-market definition, review, and distribution oversight. These are EU legal instruments, not a contractual grant of a universal right to term-life conversion. Their relevance is to the process by which complex product rights and associated customer outcomes are designed, communicated, and monitored. National implementation and specific life-product coverage still require jurisdictional review.
Replacement and consumer protection
Renewal and conversion information can be distorted by a distribution incentive to sell a replacement policy. A healthy policyholder may receive a cheaper new term offer but face changes in contestability periods or contract exclusions, whereas an impaired insured may surrender a valuable renewal or conversion right in response to a misleading comparison. The insurer or intermediary should disclose that replacement requires new underwriting and may alter coverage continuity. In the United States, NAIC life-insurance model laws provide a reference set of model conduct and replacement provisions; a model law becomes legally operative only through relevant jurisdictional adoption and text. The model's legal status must be described accurately rather than treated as a federal insurance statute.
New York's insurance policy statutory provisions (New York State Legislature, current online consolidation) illustrate the importance of verifying actual law when evaluating life-policy contract rights and grace periods. Statutory minimums, if applicable to the specific type of policy, coexist with contractual provisions and may change their enforceability. The cited section does not establish a general universal conversion privilege for all U.S. term policies; conversion eligibility in this analysis remains policy- and jurisdiction-dependent. Comparative legal research must identify the transaction date, issuance location, governing law, and the specific policy version.
Equity and access dimensions
Conversion rights can preserve protection for individuals who develop chronic illnesses or experience reduced insurability. That protection can be less effective when a new permanent premium is high relative to income, the insurer offers only costly permanent designs, or administrative frictions impede exercise. An objectively valuable conversion guarantee may therefore be underused. Assessment of fair treatment should examine practical availability and effective consumer choice, including disability access, language clarity, information needs, and predictable reminders, without claiming that every difference in take-up demonstrates unlawful discrimination. Evidence of unequal outcomes is a research finding requiring causal investigation; conclusions of illegality require the relevant legal elements.
Empirical Tests and Comparative Research
Data architecture and denominators
A serious conversion study must begin with the exact population at risk. The denominator for annual conversion incidence can be policies eligible at the beginning of the observation interval, policy-years exposed during the interval, face amount eligible for conversion, or lives at risk, depending on the research question. Their results differ. Some converted policies carry smaller face amounts than the original term policy, and a single term contract may have multiple partial conversions. Policy count and face-amount rates thus cannot be interchanged. An insurer reporting 5% of eligible face amount converted does not establish that 5% of eligible policyholders exercised any portion of their option.
The SOA/LIMRA 2009–2023 term conversion research (SOA and LIMRA, 2026 public report) is a major insurance-specific evidence contribution. Its reported contributing dataset includes 17 companies, approximately 63.6 million term-policy exposures and more than 600,000 conversion events, with corresponding converted-policy exposure and face-amount information. Its scale supports analysis of observed conversion incidence and emerging mortality patterns within participating business. The underlying participants, observation years, product definitions, and data cleaning rules limit its direct interpretation as a universal market average. Carrier participation and policy mix are not a random sample of all global term insurance.
The study's May 2026 public report provides more detailed definitions and comparisons, including conversion rates by duration, experience after conversion, and interactions with lapse behavior. Specific rate comparisons must retain the report's chosen measure, study years, and experience basis. The report's mortality ratios may use different valuation basic tables in different analyses, preventing unqualified comparison across exhibits. The responsible analytical conclusion is that the public report furnishes a substantive empirical base for study design and some descriptive patterns, while insurer-level causal inferences demand policy-form details and corresponding exposure files.
Competing-risk and multistate estimation
At each policy anniversary a term insured can remain in the initial term period, renew after level expiry, convert, lapse, surrender where permitted, die, or reach final expiry. A multistate analysis assigns transition rates to the distinct feasible next states. A straightforward duration-specific conversion hazard is number of eligible conversion exercises during interval / eligible exposure during interval, with clear handling of partial conversions. For continuous-time analysis one could estimate cause-specific hazards for conversion, lapse and death and recover cumulative incidence under competing risks. Those cumulative incidences are not equal to one minus each separate Kaplan–Meier survival curve when competing transitions prevent subsequent conversion.
Researchers should stratify or model attained age, issue age, policy duration, face amount, gender or sex where law and data permit, tobacco class where relevant, original underwriting class, mode and amount of premium, time to the option expiry, conversion-product set, level-premium period, and calendar period. Health state may be measured imperfectly, especially after the original term underwriting. Exercise is endogenous to health and financial circumstance. Even a regression that controls for recorded issue class cannot necessarily remove contemporaneous health-related selection. Conversion rates and post-conversion claims are jointly informative but not self-identifying evidence of a causal conversion effect.
The earlier SOA conversion experience report and the predictive conversion model research offer precedents for duration-based analysis and risk factor modeling. They should be compared with the newer SOA/LIMRA report using harmonized exposure measures, age periods, conversion features, and selected participating companies where data permit. Observed historical rate changes could reflect product design, option deadlines, market interest rates, new-business underwriting, carrier mix, distribution incentives, or composition rather than a pure time trend in consumer preference.
Mortality and the selection problem
Conversion incidence and mortality after conversion are two distinct statistical outcomes. Post-conversion mortality should be evaluated by duration since conversion, attained age, issue class, underwriting classification at conversion, face amount, and calendar year, with a clearly documented expected mortality basis. The denominator should use actual converted policy exposure. Comparing absolute deaths after conversion with deaths among nonconverters will mechanically confound exposure size, age, and time at risk. A defensible comparison adjusts or stratifies these factors and still acknowledges unmeasured health information.
A practical test is to estimate expected deaths under an explicitly identified mortality table and calculate an actual-to-expected ratio, with uncertainty intervals and clear weighting conventions. Low death counts can make a ratio unstable; a large overall term exposure does not guarantee precision within a narrow converted cohort. The SOA experience data resources describe available actuarial experience-study infrastructure, but no proprietary insured-life microdata are supplied in this dossier. Its numerical scenarios remain illustrative. The SOA/LIMRA 2026 public report must not be presented as though this manuscript independently re-estimated its results.
Conversion and post-level lapses interact. Some policies recorded as leaving term coverage do so because coverage is transformed; other policies lapse completely. The SOA post-level mortality and lapse update (Bradfield et al., 2021) and the SOA shock-lapse study (Rozar et al., 2010) are relevant to exits around premium jumps. Their results should be used with explicit recognition of different products, years, definitions, and selection measures. An analyst who mechanically aggregates all post-level exits and all conversions into one lapse outcome could incorrectly attribute protection transfer to loss of insurance.
Household decisions and long-duration contracting
Insurer experience data provide one vantage point; household longitudinal data provide another. Fang and Kung's life insurance lapse analysis (2012 working-paper version; later journal publication) investigates relationships among lapsation, household circumstances, and changes in health and financial need. The work concerns life insurance lapse behavior generally and should be used as contextual evidence rather than a term-conversion take-up study. It is valuable because household cash constraints and changing bequest motives can explain why even an attractive guaranteed-conversion right may remain unexercised.
Hendel and Lizzeri's theory of long-term insurance contracts (2003) studies contractual commitment and front-loaded pricing in life insurance. Its formal economic analysis illuminates why guaranteed future insurability can be valuable and why pricing a long-term commitment involves intertemporal incentives. The model does not provide empirical conversion rates for the current product market. A careful synthesis uses it as a theory of incentives and distinguishes its assumptions from contractual evidence and modern insurance-company experience.
Cross-market comparison
The source base here supports a particularly concrete comparison between U.S. actuarial experience research and selected Canadian specimen policies. The United States has a large body of SOA studies on conversion and post-level term behavior; the examined Canadian contracts offer operational evidence of age limits, policy-conversion mechanics, and risk-class rules. This is a comparison of evidence types and contract forms, not a claim that Canadian conversions are necessarily more restrictive or more common than U.S. conversions. The sources do not support that comparative empirical ranking.
The European Union contributes a different form of evidence, through the insurance distribution legal framework and product oversight requirements. These instruments inform evaluation of design governance, disclosure and target-market oversight; they do not establish an observed European conversion rate or a standardized EU-wide contract conversion clause. Comparative international research must not infer uniform policyholder rights from general distribution regulation. Future cross-country empirical work needs local specimen forms, administrative outcome data and national legal mapping before asserting systematic differences in exercise behavior.
Testable hypotheses and evidence limitations
Several hypotheses follow from established insurance economics and can be evaluated empirically without creating a new named theoretical framework. First, controlling for attained age and product eligibility, conversion incidence may rise near the option-expiry deadline if policyholders and distributors respond to a closing opportunity. Second, conversion selection may be stronger among impaired insureds where new medical underwriting is restrictive, but affordability can offset this relationship. Third, a steeper renewal premium jump may simultaneously increase conventional term lapses and demand for conversion, depending on the price of eligible permanent cover. Fourth, reminder interventions may alter the timing and frequency of conversion without changing the intrinsic value of the entitlement. Fifth, the insurer's converted cohort can display mortality different from both original issue mortality and the post-level renewal cohort, even after age adjustment.
These are research propositions, not findings established by this monograph's own experiment. An observational estimate would require pre-specified covariates, data-cleaning and censoring rules, clustered uncertainty where relevant, and appropriate validation. Estimating the effect of reminders may require randomized assignment or credible quasi-experimental variation in communication timing. Studying exercise incentives around deadlines faces the confounding effects of attained age and product design. Comparing newly available conversion products across years may suffer from concurrent carrier repricing and changes in distribution. Missing health measurements, unobserved replacement policies, and inability to link original and converted policy records are serious limitations. The absence of original policy-level data in this dossier prevents causal estimates.
Adverse scenarios and robust interpretation
The relevant stress scenarios combine contract and policyholder risk rather than isolating a single mortality assumption. A steep scheduled increase can push healthy insureds to replace term coverage; a contraction in the available permanent-product set can make conversion less attractive; deterioration in health can raise the value of conversion while reducing affordability; and operational delays can cause eligibility windows to close even when a customer intended to act. Insurer outcomes depend on the joint distribution of these states, while consumer welfare depends on feasible replacement coverage and the consequences of being uninsured.
The same hypothetical experience pattern can admit different explanations. A rise in conversions shortly before expiry could indicate rational deadline management, distributor reminders, worsened health, administrative batching or changes in permanent-product relative prices. A high mortality ratio among converted lives could reflect medical selection, age composition, table basis differences, or a mixture. Statistical design and source documentation are therefore central to causal claims. The original analytical work in this dossier is a reconciliation of contract mechanics, cash-flow logic and available experience evidence under explicit boundaries; it does not claim priority over a newly discovered result.
Scientific Synthesis and Conclusions
Contractual rights are contingent assets
The evidence establishes that term-life renewal and conversion privileges have both legal and actuarial significance. They shape the household's future feasible insurance set, and they alter the insurer's exposure to adverse selection. Their value is conditional on health, age, future prices, eligibility, product availability, and the ability to pay. A renewal privilege can preserve a death benefit for a shorter additional period. A conversion privilege can preserve access to permanent insurance when re-underwriting would otherwise limit that access. The two rights can be jointly offered, but their valuation remains separate because the future cash flows and exercise decisions differ.
This synthesis emerges from reading specimen contract terms together with insurer experience studies and insurance-economics literature. The contractual form determines the legally possible transitions. Experience research measures some realized transitions among actual policies. Actuarial projections map future transitions and claims subject to assumptions. Consumer-protection analysis evaluates whether policyholders can understand and exercise the available rights. Reconciliation across these layers strengthens each inference and exposes error when a product label substitutes for evidence.
Implications for product design
A defensible product design specifies renewal schedule, policy term, final expiry, conversion window, maximum amount, eligible replacement products, premium basis, risk-class carryover or mapping, and interaction with riders. Each choice affects the buyer's expected protection and insurer's risk. Narrower conversion windows can reduce expected insurer option exercise at later deteriorated health states, while they also reduce the policyholder's flexibility. A broader guarantee increases the potential value of continued insurability and may justify a correspondingly different initial pricing basis. Neither design is superior in every market without a specified consumer population, premium structure and welfare criterion.
The contractual distinction between guaranteed rights and administrative expectations deserves special attention. A future permanent product list, communication practice, or conversion application workflow can change. Pricing and policyholder expectations should rely on binding terms, documented eligibility rules, and precise notice language. Where a conversion promise is qualified by availability of designated permanent products, the firm should model and explain the consequences of that qualification. Where risk-class mapping is guaranteed, pricing should reflect the cohort selection that this mapping enables.
Implications for actuarial research and governance
Pricing should jointly project transition probabilities for renewal, conversion, lapse and death. Exposure units must be consistent with outcomes, and the models should test alternative health-selection, affordability and customer-response assumptions. Model validation should distinguish original-term, post-level renewal and converted-permanent populations. A mortality table may be appropriate for the base portfolio but inadequate for a selected conversion subgroup unless adjusted and supported by data. Sensitivities should include options approaching expiry, step changes in premiums and changes in eligible permanent-product terms.
Accounting, statutory reserving, internal economic value and pricing profitability require reconciled but different calculations. For example, an IFRS 17 boundary assessment can include enforceable substantive rights and current obligations, while a product pricing projection may span a broader commercial horizon or use different risk adjustments. A single unqualified present-value number cannot represent all those concepts. Reporting should identify objective, basis, period, discounting, future expenses, mortality, conversion behavior, and any ceded reinsurance effects.
Implications for consumer protection and distribution
The central consumer risk is misunderstanding what a contractual right allows and when it expires. Disclosure should make renewal price changes, conversion deadlines and actual permanent-policy options visible while there is still meaningful time to act. The process should preserve evidentiary records of policy version and delivery, accommodate accessibility needs, and handle partial conversion, beneficiary continuity and premium-payment logistics consistently with contract law. Regulators and distributors should distinguish consumer comprehension and actual exercise from mere delivery of a notice. A reliable program can test comprehension and subsequent behavior within a documented jurisdictional mandate.
Monitoring should also consider unequal effective access. A conversion provision may be legally available but financially inaccessible to some policyholders facing high permanent rates. This is analytically different from an insurer unlawfully denying a vested entitlement. Measured nonexercise can be consistent with rational budget prioritization, low perceived need, misunderstanding, or process obstacles. Policyholder outcomes should be evaluated with the feasible alternatives and household circumstances visible wherever data permit.
Integrated conclusion and research agenda
Taken together, the verified source base supports a defined conclusion: the design of renewable and convertible term-life insurance is a joint problem of contractual commitment, contingent policyholder choice, insurer risk selection and intertemporal financing. The insurer's exposure and the individual's protection change as future health information unfolds. Product value cannot be established by renewal premiums alone, conversion availability alone, or raw exercise rates alone. Each calculation needs the actual rights, the eligible population and the relevant future counterfactual.
A rigorous next empirical phase would link individual original-term policies to renewal transactions, eligible conversion offers, eventual permanent contracts, deaths, lapses and communications, with the original forms and all amendments indexed by issue cohort. It would calculate competing-risk transition probabilities, model possible selective conversion, report uncertainty at policy and face-amount levels, and independently validate mortality experience by duration since conversion. Where policyholder welfare is at issue, survey or administrative information on household alternatives and actual replacement availability is needed. International extensions should begin with local contract-law review and comparable data definitions. The research agenda is substantive and testable; it is not offered as a new theory or doctrine.
Conclusion
Term life insurance renewal and conversion rights are economically consequential options embedded in duration-limited life protection. Renewal provides contractually specified continuation possibilities, typically with future premium adjustments; conversion permits eligible transformation into designated permanent coverage under specified underwriting rules. Their interplay is determined by actual policy language, age and time limits, future prices, changes in health, policyholder affordability and the insurer's evolving risk pool. The principal scientific requirement is to connect these distinct contractual options to correctly defined cash flows and the observed transitions among policy states.
Comparative evidence from official consumer guidance, issued policy specimens, professional standards, IFRS 17 interpretation, distribution regulation, academic contract theory and SOA term conversion studies supports this integrated reading. The SOA/LIMRA 2009–2023 experience program is an important empirical basis, yet its descriptive results remain bounded by the participating portfolios and reporting conventions. The hypothetical calculations in this monograph establish mechanisms and sensitivity, not population estimates. The original contribution is a source-verified analytical synthesis of renewal price dynamics, conversion-option valuation, eligibility governance and empirical identification requirements. No new named theory, actuarial valuation standard, proprietary model, or scientific priority is asserted.
For product designers and scientific investigators, the operational result is a clear hierarchy of verification: establish the exact issued rights; define eligible exposures and competing transitions; value the contractual cash flows on an explicit basis; test joint lapse, conversion and mortality selection; and verify consumer communication against the governing contract and jurisdiction. These procedures provide an auditable foundation for better comparison of renewable and convertible term life insurance contracts across markets and time.
References
Actuarial Standards Board. 2018. Actuarial Standard of Practice No. 54: Pricing of Life Insurance and Annuity Products. Actuarial Standards Board. https://www.actuarialstandardsboard.org/asops/pricing-of-life-insurance-and-annuity-products/
Bradfield, Aisling, Carolyn Covington, Rebecca Reppert, and Julien Tomas. 2021. U.S. Post-Level Term Lapse and Mortality Experience. Society of Actuaries. https://www.soa.org/resources/experience-studies/2021/us-post-level-term-lapse-mortality/
Equitable. 2025. Term Insurance Sample Policy Pages. Equitable Life Insurance Company of Canada. Specimen policy, September 10, 2025 revision cited. https://cdn.equitable.ca/forms/unsecured/insurance/Term-Sample-Policy-Pages.pdf?v=September-10-2025
European Commission. 2017. Commission Delegated Regulation (EU) 2017/2358 of 21 September 2017, Supplementing Directive (EU) 2016/97 with Regard to Product Oversight and Governance Requirements for Insurance Undertakings and Insurance Distributors. Official Journal of the European Union. https://eur-lex.europa.eu/eli/reg_del/2017/2358/oj/eng
European Parliament and Council. 2016. Directive (EU) 2016/97 of 20 January 2016 on Insurance Distribution. Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32016L0097
Fang, Hanming, and Edward Kung. 2012. Why Do Life Insurance Policyholders Lapse? The Roles of Income, Health, and Bequest Motive Shocks. National Bureau of Economic Research, Working Paper No. 17899; subsequently published in Journal of Risk and Insurance 88 (4), 2021, 937–970. https://www.nber.org/papers/w17899
Hendel, Igal, and Alessandro Lizzeri. 2003. “The Role of Commitment in Dynamic Contracts: Evidence from Life Insurance.” Quarterly Journal of Economics 118 (1): 299–328. https://academic.oup.com/qje/article-abstract/118/1/299/1917037
IFRS Foundation / International Accounting Standards Board. 2017. IFRS 17 Insurance Contracts. As amended; effective for annual reporting periods beginning on or after January 1, 2023. https://www.ifrs.org/issued-standards/list-of-standards/ifrs-17-insurance-contracts/
IFRS 17 Transition Resource Group. 2018. Cash Flows within the Contract Boundary. Agenda Paper 3, May 2018. International Accounting Standards Board. https://www.ifrs.org/content/dam/ifrs/meetings/2018/may/trg-for-ifrs-17/ap03-cash-flows-within-the-contract-boundary.pdf
Meisinger, Lindsay, Mark Ma, Donna Megregian, and Kyle Proebsting. 2016. Report on the Conversion Experience Study for Level Premium Term Plans. Society of Actuaries. https://www.soa.org/resources/research-reports/2016/2016-report-conversion-experience-term-plans/
National Association of Insurance Commissioners (NAIC). Accessed November 2026. Life Insurance. Consumer Insurance Search and Education. https://content.naic.org/insurance-topics/life-insurance
National Association of Insurance Commissioners (NAIC). Accessed November 2026. Model Laws, Regulations and Guidelines. NAIC. https://content.naic.org/model-laws
New York Department of Financial Services. Accessed November 2026. Life Insurance. Consumer guidance and policy information. https://www.dfs.ny.gov/consumers/life_insurance
New York State Legislature. Accessed November 2026. New York Insurance Law § 3203: Individual Life Insurance Policies; Standard Provisions. Official New York State Senate legislation portal. https://www.nysenate.gov/legislation/laws/ISC/3203
New Zealand External Reporting Board (XRB). Accessed November 2026. NZ IFRS 17 Insurance Contracts. Official financial-reporting standard navigator. https://standards.xrb.govt.nz/standards-navigator/nz-ifrs-17/
RBC Insurance. Accessed November 2026. Life Insurance Disclosure. Insurer product information. https://www.rbcinsurance.com/en-ca/life-insurance/disclosure/
RBC Insurance. Sample policy. Simplified Term Life Sample Policy. Insurer specimen document. https://www.rbcinsurance.com/en-ca/wp-content/uploads/sites/2/2021/06/simplified-term-life-sample-policy-1.pdf
Rozar, Tim, Scott Rushing, and Susan Willeat. 2010. Lapse and Mortality Experience of Post-Level Premium Period Term Plans. Society of Actuaries. https://www.soa.org/resources/research-reports/2010/research-shock-lapse-report/
Society of Actuaries and LIMRA. 2026. 2009–2023 Term Conversion Experience Study. Society of Actuaries experience-study program and project overview. https://www.soa.org/resources/experience-studies/2025/2009-23-term-conversion/
Society of Actuaries and LIMRA. 2026. Term Conversion Experience Study, 2009–2023: Public Report. Society of Actuaries, May 2026. https://www.soa.org/globalassets/assets/files/resources/research-report/2026/2026-05-term-conversion-public-report.pdf
Society of Actuaries. Accessed November 2026. Experience Study Tool. SOA research tool. https://www.soa.org/resources/tables-calcs-tools/experience-study-tool/
Xu, Richard, Minyu Cao, Anthony Woods, and Mark Li. 2017. Predictive Models on Conversion Studies for Level Premium Term Plans. Society of Actuaries. https://www.soa.org/resources/research-reports/2017/predictive-models-conversion-studies/